2025-2031 Global 2-valent HPV Vaccine (2vHPV) Industry Research & Trends Analysis Report- YH Research

Home > Reports >Pharma & Healthcare > 2025-2031 Global 2-valent HPV Vaccine (2vHPV) Industry Research & Trends Analysis Report

2025-2031 Global 2-valent HPV Vaccine (2vHPV) Industry Research & Trends Analysis Report

Publication Date: 2025-10-13
Report Id: 2507745
Industry: Pharma & Healthcare
Report Page: 127
Chart: 127

PDF Download

Publication Date: 2025-10-13
Report Id: 2507745
Industry: Pharma & Healthcare
Report Page: 127
Chart: 127

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 2-valent HPV Vaccine (2vHPV) Definition
1.2 Global 2-valent HPV Vaccine (2vHPV) Market Size and Forecast
1.2.1 By Revenue, Global 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
1.2.2 By Sales Volume, Global 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
1.2.3 Global 2-valent HPV Vaccine (2vHPV) Price Trend, 2020-2031
1.3 China 2-valent HPV Vaccine (2vHPV) Market Size and Forecast
1.3.1 By Revenue, China 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
1.3.2 By Sales Volume, China 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
1.3.3 China 2-valent HPV Vaccine (2vHPV) Price Trend, 2020-2031
1.4 China Percentage in Global Market
1.4.1 By Revenue, China 2-valent HPV Vaccine (2vHPV) Share in Global Market, 2020-2031
1.4.2 By Sales Volume, China 2-valent HPV Vaccine (2vHPV) Share in Global Market, 2020-2031
1.4.3 2-valent HPV Vaccine (2vHPV) Market Size: China VS Global, 2020-2031
1.5 2-valent HPV Vaccine (2vHPV) Market Dynamics
1.5.1 2-valent HPV Vaccine (2vHPV) Market Drivers
1.5.2 2-valent HPV Vaccine (2vHPV) Market Restraints
1.5.3 2-valent HPV Vaccine (2vHPV) Industry Trends
1.5.4 2-valent HPV Vaccine (2vHPV) Industry Policy

2 Global Competitive Landscape by Company
2.1 Global 2-valent HPV Vaccine (2vHPV) Revenue by Company, 2020-2025
2.2 Global 2-valent HPV Vaccine (2vHPV) Sales Volume by Company, 2020-2025
2.3 Global 2-valent HPV Vaccine (2vHPV) Price by Company, 2020-2025
2.4 Global 2-valent HPV Vaccine (2vHPV) Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global 2-valent HPV Vaccine (2vHPV) Concentration Ratio
2.6 Global 2-valent HPV Vaccine (2vHPV) Mergers & Acquisitions, Expansion Plans
2.7 Global 2-valent HPV Vaccine (2vHPV) Manufacturers Product Type

3 China Competitive Landscape by Company
3.1 China 2-valent HPV Vaccine (2vHPV) Revenue by Company, 2020-2025
3.2 China 2-valent HPV Vaccine (2vHPV) Sales Volume by Company, 2020-2025
3.3 China 2-valent HPV Vaccine (2vHPV) 2-valent HPV Vaccine (2vHPV) Participants, Market Position (Tier 1, Tier 2, and Tier 3)
3.4 China 2-valent HPV Vaccine (2vHPV) Market, Sales Percentage of Local Players VS Foreign Players (2020-2025)
3.5 Chinese Local Players, 2-valent HPV Vaccine (2vHPV) Domestic VS Export
3.6 China Market, 2-valent HPV Vaccine (2vHPV) Import & Export
3.6.1 China Market, 2-valent HPV Vaccine (2vHPV) Import & Export, 2020-2031
3.6.2 China 2-valent HPV Vaccine (2vHPV) Import & Export Trends
3.6.3 Main Sources of China 2-valent HPV Vaccine (2vHPV) Import
3.6.4 Export Destination of China 2-valent HPV Vaccine (2vHPV)

4 2-valent HPV Vaccine (2vHPV) Production by Region
4.1 Global 2-valent HPV Vaccine (2vHPV) Capacity, Production and Capacity Utilization, 2020-2031
4.2 Global Geographic Distribution of 2-valent HPV Vaccine (2vHPV) Manufacturers
4.3 Global Major Manufacturers, 2-valent HPV Vaccine (2vHPV) Capacity Expansion and Future Plans
4.4 Global 2-valent HPV Vaccine (2vHPV) Capacity by Region
4.5 Global 2-valent HPV Vaccine (2vHPV) Production by Region
4.5.1 Global 2-valent HPV Vaccine (2vHPV) Production & Forecast by Region, 2020 VS 2024 VS 2031
4.5.2 Global 2-valent HPV Vaccine (2vHPV) Production by Region, 2020-2025
4.5.3 Global 2-valent HPV Vaccine (2vHPV) Production Market Share & Forecast by Region, 2020-2031

5 Industry Chain Analysis
5.1 2-valent HPV Vaccine (2vHPV) Industry Chain
5.2 2-valent HPV Vaccine (2vHPV) Upstream Analysis
5.2.1 2-valent HPV Vaccine (2vHPV) Core Raw Materials
5.2.2 Main Manufacturers of 2-valent HPV Vaccine (2vHPV) Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 2-valent HPV Vaccine (2vHPV) Production Mode
5.6 2-valent HPV Vaccine (2vHPV) Procurement Model
5.7 2-valent HPV Vaccine (2vHPV) Industry Sales Model and Sales Channels
5.7.1 2-valent HPV Vaccine (2vHPV) Sales Model
5.7.2 2-valent HPV Vaccine (2vHPV) Typical Distributors

6 Sights by Type
6.1 2-valent HPV Vaccine (2vHPV) Classification by Type
6.1.1 HPV16
6.1.2 HPV18
6.2 by Type, Global 2-valent HPV Vaccine (2vHPV) Market Size & CAGR, 2020 VS 2024 VS 2031
6.3 by Type, Global 2-valent HPV Vaccine (2vHPV) Revenue, 2020-2031
6.4 by Type, Global 2-valent HPV Vaccine (2vHPV) Sales Volume, 2020-2031
6.5 by Type, Global 2-valent HPV Vaccine (2vHPV) Price, 2020-2031

7 Sights by Immunization Schedule
7.1 2-valent HPV Vaccine (2vHPV) Classification by Immunization Schedule
7.1.1 2-Dose Regimen
7.1.2 3-Dose Regimen
7.2 by Immunization Schedule, Global 2-valent HPV Vaccine (2vHPV) Market Size & CAGR, 2020 VS 2024 VS 2031
7.3 by Immunization Schedule, Global 2-valent HPV Vaccine (2vHPV) Revenue, 2020-2031
7.4 by Immunization Schedule, Global 2-valent HPV Vaccine (2vHPV) Sales Volume, 2020-2031
7.5 by Immunization Schedule, Global 2-valent HPV Vaccine (2vHPV) Price, 2020-2031

8 Sights by Application
8.1 2-valent HPV Vaccine (2vHPV) Segment by Application
8.1.1 9-16 Years Old
8.1.2 16-20 Years Old
8.1.3 20-26 Years Old
8.1.4 26-45 Years Old
8.2 by Application, Global 2-valent HPV Vaccine (2vHPV) Market Size & CAGR, 2020 VS 2024 VS 2031
8.3 by Application, Global 2-valent HPV Vaccine (2vHPV) Revenue, 2020-2031
8.4 by Application, Global 2-valent HPV Vaccine (2vHPV) Sales Volume, 2020-2031
8.5 by Application, Global 2-valent HPV Vaccine (2vHPV) Price, 2020-2031

9 Sales Sights by Region
9.1 By Region, Global 2-valent HPV Vaccine (2vHPV) Market Size, 2020 VS 2024 VS 2031
9.2 By Region, Global 2-valent HPV Vaccine (2vHPV) Revenue, 2020-2031
9.3 By Region, Global 2-valent HPV Vaccine (2vHPV) Sales Volume, 2020-2031
9.4 North America
9.4.1 North America 2-valent HPV Vaccine (2vHPV) Market Size & Forecasts, 2020-2031
9.4.2 By Country, North America 2-valent HPV Vaccine (2vHPV) Market Size Market Share
9.5 Europe
9.5.1 Europe 2-valent HPV Vaccine (2vHPV) Market Size & Forecasts, 2020-2031
9.5.2 By Country, Europe 2-valent HPV Vaccine (2vHPV) Market Size Market Share
9.6 Asia Pacific
9.6.1 Asia Pacific 2-valent HPV Vaccine (2vHPV) Market Size & Forecasts, 2020-2031
9.6.2 By Country/Region, Asia Pacific 2-valent HPV Vaccine (2vHPV) Market Size Market Share
9.7 South America
9.7.1 South America2-valent HPV Vaccine (2vHPV) Market Size & Forecasts, 2020-2031
9.7.2 By Country, South America 2-valent HPV Vaccine (2vHPV) Market Size Market Share
9.8 Middle East & Africa

10 Sales Sights by Country Level
10.1 By Country, Global 2-valent HPV Vaccine (2vHPV) Market Size & CAGR，2020 VS 2024 VS 2031
10.2 By Country, Global 2-valent HPV Vaccine (2vHPV) Revenue, 2020-2031
10.3 By Country, Global 2-valent HPV Vaccine (2vHPV) Sales Volume, 2020-2031
10.4 United States
10.4.1 United States 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
10.4.2 By Company, United States 2-valent HPV Vaccine (2vHPV) Sales Volume Market Share, 2024
10.4.3 by Type, United States 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.4.4 by Application, United States 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.5 Europe
10.5.1 Europe 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
10.5.2 By Company, Europe 2-valent HPV Vaccine (2vHPV) Sales Volume Market Share, 2024
10.5.3 by Type, Europe 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.5.4 by Application, Europe 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.6 China
10.6.1 China 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
10.6.2 By Company, China 2-valent HPV Vaccine (2vHPV) Sales Volume Market Share, 2024
10.6.3 by Type, China 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.6.4 by Application, China 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.7 Japan
10.7.1 Japan 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
10.7.2 By Company, Japan 2-valent HPV Vaccine (2vHPV) Market Share, 2024
10.7.3 by Type, Japan 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.7.4 by Application, Japan 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.8 South Korea
10.8.1 South Korea 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
10.8.2 By Company, South Korea 2-valent HPV Vaccine (2vHPV) Market Share, 2024
10.8.3 by Type, South Korea 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.8.4 by Application, South Korea 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.9 Southeast Asia
10.9.1 Southeast Asia 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
10.9.2 By Company, Southeast Asia 2-valent HPV Vaccine (2vHPV) Market Share, 2024
10.9.3 by Type, Southeast Asia 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.9.4 by Application, Southeast Asia 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.10 India
10.10.1 India 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
10.10.2 By Company, India 2-valent HPV Vaccine (2vHPV) Market Share, 2024
10.10.3 by Type, India 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.10.4 by Application, India 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.11 Middle East & Africa
10.11.1 Middle East & Africa 2-valent HPV Vaccine (2vHPV) Market Size, 2020-2031
10.11.2 By Company, Middle East & Africa 2-valent HPV Vaccine (2vHPV) Market Share, 2024
10.11.3 by Type, Middle East & Africa 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031
10.11.4 by Application, Middle East & Africa 2-valent HPV Vaccine (2vHPV) Market Size, Share, 2024 VS 2031

11 Manufacturers Profile
11.1 GlaxoSmithKline Biologicals
11.1.1 GlaxoSmithKline Biologicals Company Information, Head Office, Market Area, and Industry Position
11.1.2 GlaxoSmithKline Biologicals 2-valent HPV Vaccine (2vHPV) Models, Specifications, and Application
11.1.3 GlaxoSmithKline Biologicals 2-valent HPV Vaccine (2vHPV) Sales Volume, Revenue, Price and Gross Margin, 2020-2025
11.1.4 GlaxoSmithKline Biologicals Company Profile and Main Business
11.1.5 GlaxoSmithKline Biologicals Recent Developments
11.2 Merck
11.2.1 Merck Company Information, Head Office, Market Area, and Industry Position
11.2.2 Merck 2-valent HPV Vaccine (2vHPV) Models, Specifications, and Application
11.2.3 Merck 2-valent HPV Vaccine (2vHPV) Sales Volume, Revenue, Price and Gross Margin, 2020-2025
11.2.4 Merck Company Profile and Main Business
11.2.5 Merck Recent Developments
11.3 Beijing Wantai Biological Pharmacy Enterprise
11.3.1 Beijing Wantai Biological Pharmacy Enterprise Company Information, Head Office, Market Area, and Industry Position
11.3.2 Beijing Wantai Biological Pharmacy Enterprise 2-valent HPV Vaccine (2vHPV) Models, Specifications, and Application
11.3.3 Beijing Wantai Biological Pharmacy Enterprise 2-valent HPV Vaccine (2vHPV) Sales Volume, Revenue, Price and Gross Margin, 2020-2025
11.3.4 Beijing Wantai Biological Pharmacy Enterprise Company Profile and Main Business
11.3.5 Beijing Wantai Biological Pharmacy Enterprise Recent Developments
11.4 Xiamen Innovax Biotech
11.4.1 Xiamen Innovax Biotech Company Information, Head Office, Market Area, and Industry Position
11.4.2 Xiamen Innovax Biotech 2-valent HPV Vaccine (2vHPV) Models, Specifications, and Application
11.4.3 Xiamen Innovax Biotech 2-valent HPV Vaccine (2vHPV) Sales Volume, Revenue, Price and Gross Margin, 2020-2025
11.4.4 Xiamen Innovax Biotech Company Profile and Main Business
11.4.5 Xiamen Innovax Biotech Recent Developments
11.5 Serum Institute of India
11.5.1 Serum Institute of India Company Information, Head Office, Market Area, and Industry Position
11.5.2 Serum Institute of India 2-valent HPV Vaccine (2vHPV) Models, Specifications, and Application
11.5.3 Serum Institute of India 2-valent HPV Vaccine (2vHPV) Sales Volume, Revenue, Price and Gross Margin, 2020-2025
11.5.4 Serum Institute of India Company Profile and Main Business
11.5.5 Serum Institute of India Recent Developments
11.6 Walvax Biotechnology
11.6.1 Walvax Biotechnology Company Information, Head Office, Market Area, and Industry Position
11.6.2 Walvax Biotechnology 2-valent HPV Vaccine (2vHPV) Models, Specifications, and Application
11.6.3 Walvax Biotechnology 2-valent HPV Vaccine (2vHPV) Sales Volume, Revenue, Price and Gross Margin, 2020-2025
11.6.4 Walvax Biotechnology Company Profile and Main Business
11.6.5 Walvax Biotechnology Recent Developments

12 Conclusion

13 Appendix
13.1 Research Methodology
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Market Estimation Model
13.4 Disclaimer

According to YH Research, the global market for 2-valent HPV Vaccine (2vHPV) should grow from US$ 4660 million in 2024 to US$ 7168 million by 2031, with a CAGR of 6.4% for the period of 2025-2031.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

2-valent HPV Vaccine (2vHPV)

According to YH Research, the global market for 2-valent HPV Vaccine (2vHPV) should grow from US$ 4660 million in 2024 to US$ 7168 million by 2031, with a CAGR of 6.4% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The 2-valent HPV Vaccine (2vHPV)is a prophylactic vaccine based on virus-like particles (VLPs) targeting the high-risk HPV types 16 and 18. Its primary goal is to block the key oncogenic types responsible for cervical cancer and some cancers of the vulva, vagina, and anus. Compared to multivalent vaccines, the bivalent vaccine emphasizes immunogenicity and long-term protection against the most high-risk, carcinogenic types in its focused composition. It often employs a differentiated adjuvant to enhance the breadth and memory of the immune response in young female populations. As a public health intervention tool, the 2vHPV maintains a unique position within national immunization programs, serves as a complementary vaccine option, and features in accessibility strategies tailored for low-resource settings.

Market Opportunities and Drivers: Why is it Still Worth Attention?The large population base, uncovered target demographics, and government priorities in preventive healthcare create sustained demand. The long-term policy direction of "preventing cancer through vaccination" from global health organizations and national health regulators provides institutional drive for procurement and inclusion. Meanwhile, vaccine production technologies (such as VLP expression systems and adjuvant optimization), improvements in local production capacity, and market pressures regarding price and accessibility jointly foster more product forms and supply strategies. Challenges stem from market preference for the broader protection of multivalent vaccines, the channel advantages of established brands, and differences in national procurement and reimbursement policies, which can compress the growth space for bivalent products in middle- and high-income markets. However, in cost-sensitive scenarios or where coverage of high-risk carcinogenic types is the primary goal, the bivalent vaccine remains competitive.Industry and Supply Chain: Who is Upstream, Where is Downstream?Upstream involves antigen expression systems (e.g., expression and purification of recombinant L1 protein), adjuvant and excipient technologies, as well as quality control and release systems. Representative upstream suppliers include large biopharmaceutical R&D platforms and CROs/CMOs specializing in vaccine ingredients and adjuvants. Downstream channels are primarily public health institutions, child and adolescent immunization programs, maternal and child health services, and private vaccination clinics. At the corporate level, GlaxoSmithKline (Cervarix) has long been regarded as a typical producer of the bivalent vaccine, while the Serum Institute of India and local manufacturers in China and India (such as Beijing Wantai Biological Pharmacy Enterprise and its related entities in Xiamen) reflect the trend of regionalized supply and scaled-up production. Collaborations between companies range from technology licensing to independent R&D, and from export to localized market entry. The downstream market also includes the vaccine distribution cold chain, vaccination services, and community awareness systems, which directly determine the final product coverage and market return.Market Segmentation Trends: Which Application Scenarios and End-Users Are Growing Fastest?By application scenario, school/campus immunization programs and routine adolescent immunization are the main battlegrounds for growth, as they can achieve high coverage rates in a single effort. In terms of end-users, public health procurement (government purchases, immunization programs) takes priority in coverage and scale, but private clinics and self-paid vaccinations show resilient growth following enhanced information dissemination and improved accessibility. Downstream, maternal and child health systems, school health programs, and corporate health plans (employee health) have become important expansion channels. The fastest-growing segments are typically "centralized vaccination programs targeting adolescents and schools" and regional protection strategies focused on "low-cost, localized production to improve primary-level coverage." Combining these two approaches can amplify impact and reduce vaccination gaps in the short term.Regional Trends: How Do North America, China/Asia-Pacific, Europe, and Other Regions Differ?North American and Western European markets prefer the broader coverage of multivalent options, with procurement and clinical guidelines gradually favoring nonavalent or broader-spectrum products. Consequently, the bivalent vaccine in these markets is primarily for specific groups or existing stockpiles. China and some Asia-Pacific countries have recently seen leaps in local industrialization, with domestically produced multivalent/bivalent products entering the market and intensifying price competition, leading to more flexible regional procurement and clinical choices. Europe emphasizes evidence-based inclusion in its regulations and national policies, where the bivalent vaccine remains an optional tool. Lower-middle-income countries focus more on accessibility and cost-effectiveness, where regional/national immunization plans, price negotiations, and international supply licenses (e.g., product authorizations for SII) directly influence the market space for bivalent products. Overall, regional differences are shaped by three key factors: policy tendencies, payment capacity, and local production capability.Latest DevelopmentsDecember 16, 2022: The World Health Organization updated its HPV vaccine position paper, continuing to endorse HPV vaccination as a core public health measure for preventing cervical cancer and outlining the suitability and vaccination schedules for bivalent, quadrivalent, and nonavalent vaccines in different contexts；During 2023: The Serum Institute of India launched and advanced the market entry and promotion of its local HPV vaccine (CERVAVAC), marking the emergence of more large-scale suppliers from emerging markets in the global vaccine supply landscape；February 4, 2025: Merck announced a temporary halt to shipments of Gardasil to the Chinese market, reflecting short-term fluctuations in demand, channels, and the competitive landscape in China. This move has a direct impact on the competitive dynamics and inventory management of both multivalent and bivalent products locally.

This report aims to provide a comprehensive study of the global market for 2-valent HPV Vaccine (2vHPV).
Report Highlights:
(1) Global 2-valent HPV Vaccine (2vHPV) market size (sales volume & revenue), history data from 2020-2025, and forecast data from 2026 to 2031.

(2) Global 2-valent HPV Vaccine (2vHPV) market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(3) China 2-valent HPV Vaccine (2vHPV) market competitive situation, sales, revenue, price, and market share, from 2020 to 2025.

(4) Global 2-valent HPV Vaccine (2vHPV) segment by region (or country), key regions cover the United States, Europe, China, Japan, South Korea, Southeast Asia, and India, etc.

(5) Global 2-valent HPV Vaccine (2vHPV) segment by Type, and by Application, and regional segment by Type, and by Application.

(6) Global major production regions of 2-valent HPV Vaccine (2vHPV), capacity, production and trends.

(7) 2-valent HPV Vaccine (2vHPV) industry supply chain, upstream, midstream, and downstream analysis.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by Type, covers
HPV16
HPV18

Market segment by Immunization Schedule, covers
2-Dose Regimen
3-Dose Regimen

Market segment by Application, can be divided into
9-16 Years Old
16-20 Years Old
20-26 Years Old
26-45 Years Old

Market segment by players, this report covers
GlaxoSmithKline Biologicals
Merck
Beijing Wantai Biological Pharmacy Enterprise
Xiamen Innovax Biotech
Serum Institute of India
Walvax Biotechnology